Efficacy of Upadacitinib Maintained for 3 Years for Those With Psoriatic Arthritis
June 7th 2023Previously, upadacitinib improved symptoms through 2 years in the SELECT-PsA 1 trial for those with psoriatic arthritis with prior inadequate response or intolerance to ≥1 non-biologic disease-modifying antirheumatic drug.
Read More
FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications
June 6th 2023The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Read More
Obstructive Sleep Apnea May Have Significant Impact on Cognitive Decline in Middle-Aged Individuals
June 6th 2023Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.
Read More
Targeting Folate Receptor Alpha Provides Therapeutic Benefits for Platinum-Resistant Ovarian Cancer
June 5th 2023Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.
Watch
Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC
June 5th 2023Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.
Read More